Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALG-055009 in MASH (HERALD)
NCT06342947Phase 2Completed
- Sponsor
- Aligos Therapeutics
- Start
- Apr 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ALG-055009 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Aligos Therapeutics. Started Apr 2024; status: completed.
02
Drugs
ALG-055009
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06342947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342947.